Qu Jieming, Li Zhuozhe, He Lixian, Sun Bo, Chen Xuehua
Department of Pulmonary Medicine, Zhongshan Hospital, Institute of Respiratory Diseases, Fudan University, Shanghai 200032, China.
Chin Med J (Engl). 2002 Jul;115(7):1099-100.
Pulmonary surfactant ( PS ) compromises lipids and surfactant proteins (SP) and lines on the alveolar air-liquid interface. It can reduce surface tension, prevent alveoli from collapse and reduce alveoli edema by disaturated dipalmitoylphosphatidylcholine. It also modulates the pulmonary immunology by SP-A and SP-D. In this study,we established a rat model of immunocompromised host (ICH) with pulmonary infection of Pseudomonas aeruginosa (P. aeruginosa), then studied its pulmonary inflammatory reaction and analyzed the concentration of lipids and SP-A in bronchoalveolar lavage fluid (BALF) during infection.
肺表面活性物质(PS)由脂质和表面活性蛋白(SP)组成,位于肺泡气液界面。它可以降低表面张力,通过二棕榈酰磷脂酰胆碱防止肺泡塌陷并减轻肺泡水肿。它还通过SP-A和SP-D调节肺部免疫。在本研究中,我们建立了铜绿假单胞菌肺部感染的免疫功能低下宿主(ICH)大鼠模型,然后研究其肺部炎症反应,并分析感染期间支气管肺泡灌洗液(BALF)中脂质和SP-A的浓度。